Objectives: Persistent type II endoleaks have generally been thought to result from too much blood flow in the aortic sac. Although some anatomic factors, such as number of aortic branches and use of anticoagulants, have been linked to type II endoleaks following endovascular aneurysm repair (EVAR), few studies have examined the potential role of instructions for use (IFU) violations and tenuous endograft sealing resulting in transmitted endotension, which may act as a promoter of persistent and clinically significant type II endoleaks. We examined the role of anatomic factors, clinical factors, and IFU violations in predicting the presence of clinically significant type II endoleaks.
Objectives: Persistent type II endoleaks have generally been thought to result from too much blood flow in the aortic sac. Although some anatomic factors, such as number of aortic branches and use of anticoagulants, have been linked to type II endoleaks following endovascular aneurysm repair (EVAR), few studies have examined the potential role of instructions for use (IFU) violations and tenuous endograft sealing resulting in transmitted endotension, which may act as a promoter of persistent and clinically significant type II endoleaks. We examined the role of anatomic factors, clinical factors, and IFU violations in predicting the presence of clinically significant type II endoleaks.
Methods: This multicenter retrospective observational study included patients undergoing elective EVAR from 2005 to 2014. Preoperative computed tomography scans were reviewed using a standardized anatomic scoring system, and IFU violations were tabulated on a device-specific basis. Demographic, anatomic, and follow-up data were collected, and predictors of clinically significant type II endoleaks were determined. Type II endoleaks were considered significant if they persisted >1 year and were associated with sac expansion, reintervention, or persistence of aortic sac diameter. Factors associated with clinically significant type II endoleaks were analyzed using c 2 test or t-test where appropriate.
Results: Complete follow-up data were available for 429 patients, with a mean follow-up of 2 years. Type II endoleaks occurred in 21% (n ¼ 90) of patients, with 44% (n ¼ 40) of type II endoleaks considered significant. Predictors of clinically significant type II endoleaks included number of patent aortic sac branches (mean, 6.2 vs 4.7; P ¼ .001), and less circumferential aortic thrombus in the aortic sac (P ¼ .012). Patients with significant type II endoleaks were more likely to have a graft placed in violation of IFU (60.0% vs 40.9%; P ¼ .02). Clinical parameters, anticoagulant use, and antiplatelet use were not associated with type II endoleaks.
Conclusions: IFU violation appears to be associated with the occurrence of significant type II endoleaks, perhaps through tenuous graft sealing and transmitted pressure that promotes persistence of the endoleak and growth of the aortic sac. Patients who have grafts implanted outside the IFU and have greater than five patent aortic sac branches and minimal aortic thrombus may benefit from preoperative embolization of aortic sac branches.
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IP049. Percutaneous Endovascular Aortic Aneurysm Repair Is Feasible for Ruptured Abdominal Aortic Aneurysms
Results: Eleven patients were identified during the study period. All patients had a preoperative computed tomography angiography diagnosing rAAA, 91% (10 of 11) had evidence of hemorrhagic shock at time of admission, and all patients underwent emergent repair. rPEVAR main body sheath size (18.5F 6 1.8F), technical success (100%), and ipsilateral main body femoral artery access site closure success (100%) were not significantly different from ePEVAR patients. However, compared to ePE-VAR, rPEVAR was associated with increased need for blood transfusion (91% vs 4%; P < .01) and length of stay in the intensive care unit (5.8 vs 1.1 days; P < .01) and hospital (10 vs 1.3 days; P < .01). There was no difference in major adverse events (27% vs 6%; P ¼ .07) and vascular complications between groups (0% vs 12%; P < .58).
Conclusions: Compared to recent trial data demonstrating reduced access site complications with ePEVAR, rPEVAR appears to also have acceptable access site results. Although patients undergoing rPEVAR have higher morbidity and longer postoperative hospital stays, the method of percutaneous femoral cannulation does not appear to increase the risk of the aneurysm repair. Objectives: Open abdominal aneurysm repair (OAR) is associated with higher risk of mortality compared to endovascular repair (EVAR). The aim of this study was to compare failure to rescue (FTR) in patients who develop in-hospital major complications after OAR and EVAR.
Methods: Patients who had OAR or EVAR and any in-hospital complication in the American College of Surgeons National Surgical Quality Improvement Program 2011 to 2015 were selected. Patients with ruptured aneurysm or with type IV thoracoabdominal aneurysms were excluded. Primary outcome was FTR, defined as mortality in patients who developed at least one complication. Univariable and multivariable statistics were used.
Results: A total of 12,452 patients were identified. Of those, 3341 (26.8 %) had at least one in-hospital major complication, mostly occurring after OAR (76.4% vs 15.1%; P < .001). Most common in-hospital complications after both procedures were postoperative blood transfusion, respiratory complications, acute kidney injury, and ischemic colitis. Pneumonia, failure to wean off ventilator, wound dehiscence, septic shock, progressive renal insufficiency, deep vein thrombosis, and aneurysm rupture were significantly more common after OAR, whereas stroke, myocardial infarction, and lower extremity ischemia were significantly higher after EVAR (Table I) . Almost one-third of patients had more than one complication during their hospital stay (OAR: 36.3% vs EVAR: 28.0%; P < .001). On the other hand, w19.8% of patients developed further complications after discharge (OAR: 18.4% vs EVAR: 21.6%; P ¼ .02). No difference in FTR was 
